Search clinical trials for: celecoxib, NPC, gefitinib

Total 388 results

London School of Hygiene and Tropical Medicine

Completed

Single Low Dose Tafenoquine to Reduce P. Falciparum Transmission in Mali (NECTAR2) (NECTAR2)

Malaria, Falciparum

Mali
Kadmon Corporation, LLC

Completed

Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or Erlotinib

Carcinoma, Non-Small-Cell Lung

United States
MedImmune LLC
AstraZeneca

Completed

MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).

Carcinoma, Non-Small-Cell Lung

United States, Korea, Republic of, Japan
AstraZeneca

Terminated

Gefitinib Long-term Survivor Study

EGFR Mutation Positive Advanced Non-small-cell Lung Cancer

China
M.D. Anderson Cancer Center
GlaxoSmithKline; AstraZeneca

Completed

Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer

Peritoneal Neoplasms | Ovarian Cancer | Fallopian Tube Cancer

United States
Daiichi Sankyo, Inc.
Daiichi Sankyo UK Ltd.

Terminated

A Study of DS-2248 in Participants With Advanced Solid Tumors

Non-small Cell Lung Carcinoma | Solid Tumors

United States
National Institute for Medical Research, Tanzania
Universiteit Antwerpen

Unknown

Effectiveness and Safety of Intermittent Preventive Treatment for Malaria Using Either Dihydroartemisinin-piperaquine or Artesunate-amodiaquine in Reducing Malaria Related Morbidities and Improving Cognitive Ability in School-aged Children in Tanzania (InSMART-school)

Anemia | Malaria,Falciparum

Tanzania
CHU de Reims

Terminated

Randomised, Evaluation-blinded, Crossover, Controlled Study Assessing Dynamic Hand Splinting in Adults With Post-stroke Hemiplegia (Orthox) (ORTHOX)

Upper Limb Spasticity

France
National Cancer Centre, Singapore

Completed

PRe-Operative Gefitinib in Resectable EGFR Mutation Positive Lung Cancer With Sector Sequencing for Biomarker Discovery (PROGRESS)

Non-small Cell Lung Cancer

Singapore
Novartis Pharmaceuticals

Completed

A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment

Non-small Cell Lung Cancer

China, Taiwan, Belgium, Netherlands, Spain, Germany, Singapore, Italy, Japan, Australia, Israel, Korea, Republic of, Thailand, France
Amsterdam UMC, location VUmc

Terminated

Iressa Re-challenge in Advanced NSCLC EGFR-mutated Patients (IRENE)

Lung Cancer

Netherlands
Samsung Medical Center

Completed

Gilotrif (Afatinib) in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib

Non-small Cell Lung Cancer
Stanford University

Withdrawn

Botulinum Toxin Injection for Functional Popliteal Artery Entrapment Syndrome

Popliteal Artery Entrapment Syndrome | Functional Popliteal Artery Entrapment Syndrome

United States
Sichuan Provincial People's Hospital

Terminated

Stereotactic Body Radiation Therapy (SBRT) in Newly Diagnosed Advanced Staged Lung Adenocarcinoma (Sindas) (Sindas)

Stage IV EGFR Mutated Non-Small Cell Lung Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Drug-drug Interaction Study of Gefitinb on Apatinib in NSCLC Patients

NSCLC

China
Intergroupe Francophone de Cancerologie Thoracique

Completed

Lung Cancer in Women Treated With Anti-oestrogens anD Inhibitors of EGFR (LADIE)

Stage IV Lung Cancer

France
National Cancer Institute (NCI)
NRG Oncology

Completed

Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma Multiforme

Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma

United States
AstraZeneca

Completed

A Study of IRESSA Treatment Beyond Progression in Addition to Chemotherapy Versus Chemotherapy Alone (IMPRESS)

Non-Small Cell Lung Cancer

Italy, Spain, France, Korea, Republic of, Hungary, Japan, China, Taiwan, Hong Kong, Germany, Russian Federation
London School of Hygiene and Tropical Medicine
University of Sheffield; Institute of Tropical Medicine, Belgium

Completed

RHOST-cRCT, Reactive Household-based Self-administered Treatment Against Residual Malaria Transmission (RHOST)

Malaria

Gambia
Qilu Pharmaceutical Co., Ltd.

Unknown

Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance

Non-small-cell Lung Cancer

China
Henan Cancer Hospital

Unknown

S-1 Plus Gefitinib Versus Gefitinib Monotherapy in Patients With EGFR-sensitive Mutation Advanced Non-squamous NSCLC

Advanced NSCLC With EGFR Mutation

China
Fudan University

Unknown

Bevacizumab Combined With Gefitinib in the Treatment of Advanced NSCLC

PFS

China
Sungkyunkwan University
Ministry of Food and Drug Safety, Korea

Unknown

PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study

Carcinoma, Non-Small-Cell Lung | Immune-Related Adverse Events
Hutchison Medipharma Limited
AstraZeneca

Completed

A Phase I Study of Safety and Pharmacokinetics of Volitinib in Combination With Gefitinib in EGFR(+) NSCLC

Non-Small Cell Lung Cancer

China
Second Affiliated Hospital of Nanchang University
Nanchang University

Unknown

Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With Gefitinib

Non-small Cell Lung Cancer | EGFR Gene Mutation

China
Boehringer Ingelheim

Completed

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Lung Neoplasms

Hong Kong, Korea, Republic of, Spain, Singapore, China, United Kingdom, Taiwan, Canada, Australia, Germany, Ireland, Sweden, France, Norway
NCIC Clinical Trials Group

Completed

ZD 1839 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

Prostate Cancer

Canada
Guangdong Association of Clinical Trials
Peking University First Hospital; Zhejiang Cancer Hospital; Peking University... and other collaborators

Unknown

Gefitinib Versus Vinorelbine/Platinum as Adjuvant Treatment in Stage II-IIIA(N1-N2) NSCLC With EGFR Mutation (ADJUVANT)

Non-small Cell Lung Cancer

China
Guangdong Association of Clinical Trials

Completed

Third-line Treatment of Gefitinib in NSCLC Patients

Non Small Cell Lung Cancer

China
Allist Pharmaceuticals, Inc.

Unknown

Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer （FLAG）

Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer

China
University Hospital Regensburg

Completed

Psychometric Properties of the EORTC QLQ-LC29

Lung Cancer

Germany
Novartis Pharmaceuticals

Withdrawn

Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations

Carcinoma, Non-small Cell Lung
Hutchison Medipharma Limited

Completed

A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer

NSCLC

China
Sun Yat-sen University

Unknown

Gefitinib in Combination With Anlotinib or Placebo in Previously Untreated EGFR-mutant NSCLC (FL-ALTER)

Lung Cancer, Nonsmall Cell

China
University of Maryland, Baltimore
National Cancer Institute (NCI); University of Maryland Greenebaum Cancer Center

Completed

ZD 1839 in Treating Patients With Stage IV or Recurrent Kidney Cancer

Kidney Cancer

United States
Eli Lilly and Company

Completed

A Study of Pemetrexed and Gefitinib Versus Gefitinib in Non-Small Cell Lung Cancer (NSCLC)

Carcinoma, Non Small Cell Lung

Taiwan, Japan, Korea, Republic of, China
National Cancer Institute (NCI)

Completed

Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer

Squamous Cell Carcinoma of the Skin | Recurrent Skin Cancer

United States
AstraZeneca
Quintiles, Inc.

Completed

Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (Stage IIIB-IV)

United States
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Gefitinib in Treating Patients With Persistent or Recurrent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma

United States
Guangdong Association of Clinical Trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI

NSCLC

China
M.D. Anderson Cancer Center

Completed

Allogeneic Stem Cell Transplantation for Myelofibrosis and Myelodysplastic Syndrome

Myelofibrosis

United States
Tan Tock Seng Hospital
AstraZeneca; Singapore Cancer Syndicate.

Unknown

Adjuvant Therapy of Gefitinib (Iressa, ZD1839) in Patients With Resectable Hepatocellular Carcinoma

Liver Cancer

Singapore
Shanghai University of Traditional Chinese Medicine
Shanghai Chest Hospital; Shanghai Pulmonary Hospital, Shanghai, China

Completed

Clinical Study of Chinese Medicine Plus Targeted Therapy Maintenance in Advanced Pulmonary Adenocarcinoma

Cancer
Shanghai University of Traditional Chinese Medicine
Shanghai Chest Hospital; Shanghai Pulmonary Hospital, Shanghai, China

Unknown

Clinical Study of YYJD Decoction Combined With Gefitinib in Advanced Pulmonary Adenocarcinoma

Cancer
Guangzhou Medical University

Unknown

Pemetrexed/Cisplatin Intercalating Gefitinib Treating EGFR Wild NSCLC

Non Small Cell Lung Cancer

China
AstraZeneca

Approved for marketing

An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer of the Head and Neck

Non Small Cell Lung Cancer | Cancer of the Head and Neck

Poland, Germany, Hungary, United Kingdom
Oslo University Hospital
The Research Council of Norway

Completed

N-of-1 Trial: Actionable Target Identification in Metastatic Cancer for Palliative Systemic Therapy (MetAction)

Metastatic Cancer

Norway
Astellas Pharma Global Development, Inc.

Terminated

A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations (SOLAR)

Non-small Cell Lung Cancer (NSCLC)

United States, Australia, Belgium, Canada, Chile, France, Germany, Hungary, Italy, Japan, Korea, Republic of, Malaysia, Netherlands, Peru, Portugal, Romania, Russian Federation, Singapore, Spain, Taiwan, Thailand, Ukraine, United Kingdom
The First Affiliated Hospital of Soochow University
Affiliated Hospital of Jiangnan University; Chia Tai Tianqing Pharmaceutical... and other collaborators

Unknown

Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung Cancer

Non-Small-Cell Lung

China
Yonsei University

Unknown

A Phase III, Randomized, Multi-center Study to Determine the Efficacy of the Intercalating Combination Treatment of Chemotherapy and Gefitinib or Chemotherapy as Adjuvant Treatment in NSCLC With Common EGFR Mutations.

Completely Resected NSCLC With Common EGFR Mutations

Korea, Republic of

Search clinical trials for: celecoxib, NPC, gefitinib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Greece

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations